Nuhou Uea

ʻO ka Mechanism Medical Cannabis hou no nā keiki me ka maʻi Autism Spectrum 

i kakauia ma hoʻoponopono

Ua hoʻolaha ʻo Cannformatics ua ʻike ʻia he 22 mau mea biomarkers hiki ke hoʻokumu i ka lipid-based Cannabis-Responsive ™ i loko o ka kohu o nā keiki me ka autism spectrum disorder (ASD). Ua neʻe ka 22 biomarkers i ka pae physiological o ka hoʻomohala maʻamau o nā keiki ma hope o ka mālama ʻana i ka cannabis lapaʻau kūleʻa. Aia kēia mau biomarkers i nā lipid o ka ʻōnaehana nerve waena e pili ana i ka hana cellular i loko o ka lolo e hōʻike ana i ka hiki i ka cannabis lapaʻau ke hopena i ka hana neuron i nā keiki me ASD. Ke hoʻomau nei kēia mau ʻike i ka holomua o ka ʻoihana i ka hoʻomaka ʻana i kahi lawelawe lāʻau lapaʻau pilikino ma ke ʻano he kumu i nā mea mālama olakino a me nā mea maʻi e makemake ana e hoʻohana i nā lāʻau lapaʻau a me nā huahana cannabinoid e mālama i nā kūlana olakino paʻakikī.

Ua hoʻopuka ka hui i kāna mau ʻike ma ka puke pai Cannabis a me Cannabinoid Research i kahi pepa i kapa ʻia, "ʻO ka hiki o ka salivary lipid-based Cannabis-Responsive biomarkers e loiloi i ka lāʻau lapaʻau cannabis i nā keiki me ASD." ʻO kēia pepa ka pepa ʻelua e hele mai ana mai ka ʻoihana ASD Pilot study. ʻO ka pepa mua i paʻi ʻia ma Dekemaba 2021 i hoʻokumu i nā biomarkers Cannabis-Responsive ma ke ʻano he mea hana honua no ke ana ʻana i ka hopena olakino. ʻO ka hui pū ʻana o nā pepa ʻelua e hōʻike ana i ka hiki o nā biomarkers Cannabis-Responsive i hoʻokumu ʻia i ka saliva e lilo i mea hana no nā kauka ʻelua e mālama ana i nā maʻi me ka cannabis lapaʻau a me nā ʻoihana ʻepekema ola e hoʻomohala ana i nā lāʻau a me nā noi cannabinoid.

"Ma ka wehe ʻana i ke ʻano hana o ka cannabis lapaʻau, hōʻike mākou e hiki i nā biomarkers Cannabis-Responsive ke hāʻawi i nā ʻoihana ʻepekema ola a me nā kauka i nā mea hana hou no ka hoʻomaopopo ʻana i ka hana o ka cannabis i ka mālama ʻana i ka homeostasis o ka ʻōnaehana nerve waena i nā keiki me ASD. Ke wehe nei kēia haʻawina i nā manawa hou e loiloi i ka mālama ʻana i ka cannabis lapaʻau i nā maʻi neurodegenerative e like me ka maʻi o Alzheimer, ka maʻi Parkinson a me ALS, kahi i ʻike ʻia ai kekahi o kēia mau lipid-based Cannabis-Responsive biomarkers e pāʻani i kahi kuleana ", wahi a Itzhak Kurek, PhD. , Luna Nui a me ka hoʻokumu pū o Cannformatics. "Aia mākou i kēia manawa i ka hoʻonui ʻana i ke kapikala e pono ai e hoʻomaka i ka kahua lawelawe ASD a hoʻonui i nā maʻi neurodegenerative."

"ʻO ka paʻi ʻana o kēia pepa ʻelua he manawa koʻikoʻi ia no Cannformatics no ka mea e hōʻoia piha ʻo ia i kā mākou ʻenehana a hoʻonoho maopopo iā mākou ma ke ʻano he alakaʻi biotechnology i ka mālama ʻana i ka cannabis lapaʻau," wahi a Kenneth Epstein Luna Nui Kalepa a me ka cofounder o Cannformatics. "Ke hoʻomau nei mākou i ka mahalo i nā keiki a me nā ʻohana i komo i ke aʻo ʻana a me kā mākou mea kākoʻo Canniatric a me Whole Plant Access for Autism. Ua ʻoi aku ka maikaʻi o nā ʻike mai kēia haʻawina ma mua o ko mākou manaʻo. "

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...